Needham Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

By Austin Angelo

Needham analyst Alan Carr reiterated a Buy rating on Crispr Therapeutics AG (CRSPResearch Report) yesterday and set a price target of $62. The company’s shares closed yesterday at $50.72.

According to TipRanks.com, Carr is a 3-star analyst with an average return of 2.3% and a 41.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Crispr Therapeutics AG has an analyst consensus of Strong Buy, with a price target consensus of $69.69, implying a 37.4% upside from current levels. In a report issued on July 26, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a $72 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $59 and a one-year low of $22.22. Currently, Crispr Therapeutics AG has an average volume of 543.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.